Annual report pursuant to Section 13 and 15(d)

General Organization and Business (Details)

v3.20.1
General Organization and Business (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 12, 2018
Tranches
shares
Nov. 10, 2010
USD ($)
Jul. 31, 2019
USD ($)
May 31, 2019
USD ($)
Apr. 30, 2019
USD ($)
Number
Mar. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
General Organization and Business (Textual)                
Common stock issued to shareholders             $ 1,250,000
Accumulated deficit             (27,106,348) (23,412,269)
Net cash used in operating activities             (1,195,938) (883,841)
Cash in hand             6,700  
Advance from related parties     $ 402,027 $ 50,000        
Proceeds from issuance of notes payable to related parties             $ 1,190,172 $ 480,437
Related party             During October and November 2019, the Company was advanced an additional $349,000 from a related party. In addition, on January 3, 2020, the Company was advanced an additional $250,000 from a related party.  
10% Notes Payable [Member]                
General Organization and Business (Textual)                
Percentage of outstanding common stock           10.00%    
Proceeds from issuance of notes payable to related parties         $ 339,144 $ 50,000    
Number of related party | Number         2      
Contribution Agreement [Member] | CureDM Group Holdings, LLC [Member]                
General Organization and Business (Textual)                
Number of shares issued | shares 47,741,140              
Number of shares issued at time of delivered | shares 25,000,000              
Number of shares issued at time of milestone | shares 22,741,140              
Number of shares issued per tranche | shares 5,685,285              
Number of tranches for delivered | Tranches 4              
Boston Therapeutics, Inc. [Member]                
General Organization and Business (Textual)                
Accumulated deficit             $ 27,100,000  
Boston Therapeutics, Inc. [Member] | Agreement and Plan of Merger [Member]                
General Organization and Business (Textual)                
Common stock issued to shareholders   $ 4,000,000            
Percentage of outstanding common stock   100.00%